Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ: BSCT)

Latest news for Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ:BSCT)

The Fund generally will invest at least 80 percent of its total assets in securities that comprise the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, Invesco Indexing LLC (the Index Provider) compiles and maintains the Underlying Index. The Underlying Index seeks to measure the performance of a portfolio of U.S. dollar-denominated investment grade corporate bonds with maturities or, in some cases, effective maturities in the year 2029 (collectively, 2029 Bonds). Certain bonds in which the Fund may invest may contain embedded issuer call options. An embedded issuer call option means that the bonds issuer has the right to redeem a bond prior to its designated maturity date. 

Invesco BulletShares 2029 Corporate Bond ETF

News

Offerings

NAAS

NaaS Technology Inc Files For Offering Up To 4.8M American Depositary Shares

Buybacks

EBAY

On December 12, 2024, eBay Board Authorizes Incremental $3B Under Stock Repurchase Program, In Addition To Remaining Amounts Previously Authorized - Filing

BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today issued the following statement:
BD has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed investigation related to prior public disclosures and SEC reporting regarding the BD Alaris&#x2122; System, which was acquired by BD from CareFusion in 2015 and is part of the BD Medication Management Solutions business.
The SEC Order, the findings of which BD neither admits nor denies, relate to matters concerning BD Alaris that occurred more than four years ago. As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in the company's fiscal year 2024 Form 10-K and was contemplated in BD's fiscal year 2025 cash flow plan. No financial restatements are required as a result of the settlement, and the settlement amount does not impact BD's investments in innovation or its previously disclosed capital allocation strategy. BD is not updating its fiscal 2025 guidance as a result of the settlement. The company believes that settling with the SEC is the right course of action to fully resolve this matter and move forward.
The BD Alaris&#x2122; System is safe and effective and is a critical part of health care in the United States. The system has been used for many years to safely deliver IV therapies to patients, including throughout the COVID-19 pandemic. The updated BD Alaris&#x2122; System received 510(k) clearance from the U.S. Food and Drug Administration in July 2023, and the company continues to update its Alaris fleet.
BD has implemented a number of improvements to its operational and governance processes and related disclosure practices. BD is committed to operating with integrity and the highest ethical standards to produce high-quality, safe and effective products and serve as a trusted partner for its customers and their patients.

Legal

BD Resolves Previously Disclosed SEC Investigation Related To Prior Public Disclosures And SEC Reporting Regarding The BD Alaris System; BD Has Agreed To Pay $175M To The SEC; BD Is Not Updating Its Fiscal 2025 Guidance As A Result Of The Settlement

The earnings results for Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) for Q4 were made public on Monday, December 16, 2024 at 04:35 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Compass Minerals Intl missed estimated earnings by -71.0%, reporting an EPS of $-0.77 versus an estimate of $-0.45.
Revenue was down $24.80 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company missed on EPS by $0.27 in the previous quarter, leading to a 3.0% drop share price change the next day.
Here's a look at Compass Minerals Intl's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.74</td>
<td>0.27</td>
<td>0.26</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.01</td>
<td>1.49</td>
<td>0.05</td>
<td>-0.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>197.77M</td>
<td>406.92M</td>
<td>357.90M</td>
<td>231.26M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>202.90M</td>
<td>364.00M</td>
<td>341.70M</td>
<td>233.60M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Compass Minerals Intl <a href="https://www.benzinga.com/quote/CMP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Compass Minerals Intl: Q4 Earnings Insights

Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific guidance related to the timing of bookings.

Guidance

STRM

Streamline Health Reiterates $15.5M Implemented SaaS ARR Adjusted EBITDA Breakeven Run Rate Expectation; Accelerates Expectation For Achievement The Goal To H1 Of FY25

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.45) by 71.11 percent. This is a 1183.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $208.80 million which missed the analyst consensus estimate of $209.00 million by 0.10 percent. This is a 10.62 percent decrease over sales of $233.60 million the same period last year.

Earnings Misses

Compass Minerals Intl Q4 Adj $(0.77) Misses $(0.45) Estimate, Sales $208.80M Miss $209.00M Estimate

Management

Ryder System Announced The Appointment Of John J. Diez To President And COO, Effective January 1, 2025

Streamline Health Q3 EPS $(0.61) Up From $(3.15) YoY, Sales $4.42M Down From $6.13M YoY

CENT

Central Garden & Pet Increases Authorization Under Stock Repurchase Program; To Purchase Up To An Additional $100M Of Issued And Outstanding Shares

Fiscal Year 2025 Guidance
Amentum affirms its fiscal year 2025 guidance originally presented at Capital Markets Day on August 13, 2024 and provides Adjusted Diluted Earnings Per Share (EPS) guidance.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in millions, except per share data)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="7" rowspan="1">Fiscal Year 2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$13,800</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$14,200</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,060</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,100</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.00</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.20</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$475</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$525</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="9" rowspan="1">1 – Represents a Non-GAAP financial measure - see the related explanations included elsewhere in this release. Amentum does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures due to the inherent difficulty in forecasting and quantifying certain significant items. These items are uncertain, depend on various factors and could have a material impact on GAAP reported results for the relevant period.</td>
</tr>
</tbody>
</table>
</figure>

AMTM

Amentum Holdings Sees FY25 EPS $2.00-$2.20; Revenue $13.8B-$14.2B

Biotech

Events

General

TNYA

Tenaya Therapeutics To Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 Gene Therapy For MYBPC3-Associated Hypertrophic Cardiomyopathy On Dec. 17, 2024

Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.26 by 7.69 percent. The company reported $2.21 billion in sales this quarter. This is a 3.51 percent increase over sales of $2.14 billion the same period last year.

Earnings Beats

Amentum Holdings Q3 EPS $0.28 Beats $0.26 Estimate, Sales $2.21B Up From $2.14B YoY

Phase 3 KEYFORM-008 trial evaluated the fixed-dose combination of favezelimab and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) whose disease has progressed following prior anti-PD-1 therapy.&nbsp;
Patients currently in this trial may continue on therapy until study completion. KEYFORM-008 is the only Phase 3 study in the KEYFORM clinical development program for which results are not available.&nbsp;
The company has made this decision after a thorough evaluation of data from the favezelimab clinical program and will prioritize the development of other candidates in its comprehensive and diversified oncology pipeline. This decision is not based on any concerns about the safety of this fixed-dose combination.

Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
&nbsp;
&nbsp;

Merck Reports Discontinuation Of Clinical Development Programs For Vibostolimab, An Anti-TIGIT Antibody, And Favezelimab, An Anti-LAG-3 Antibody

WIIM

RCAT

Red Cat Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.

RICK

Rick Hospitality shares are trading higher after the company reported better-than-expected Q4 financial results.

BNIX

Bannix Acquisition Extends Initial Business Combination From Dec. 14 2024 To Jan. 14, 2025.

In times of geopolitical uncertainty, investors often turn to stable assets like Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) <a href="https://www.benzinga.com/partner/commodities/24/12/42459580/some-anticipate-a-bear-market-in-2025-but-geopolitical-conflicts-may-continue-to-drive-gold-p">to protect their wealth.</a>
Just recently, AFP <a href="https://www.yahoo.com/news/under-fire-scholz-trigger-german-135928390.html?fr=sycsrp_catchall">reported </a>that German Chancellor Olaf Scholz lost a confidence vote, essentially marking the conclusion of his embattled administration. This political upheaval, coupled with the <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42465746/french-government-collapse-challenges-macrons-grip-on-power">French government&#8217;s collapse</a> earlier this month, has set the stage for safe-haven speculation.
Billed as the world&#8217;s leading gold company, NEM stock represents a proxy for the precious metal. Historically, investors have viewed gold as the ultimate form <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41390144/gold-could-reach-3-000-by-2025-bank-of-america-analyst-says-ultimate-perceived-safe">of wealth preservation.</a>
Another fundamental catalyst for higher precious metal prices is inflation. Analysts widely expect the Federal Reserve to announce a 25-basis-point <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">rate cut</a> on Wednesday. Naturally, this anticipated action has reignited inflation concerns, which, all other things being equal, should be positive for gold.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1022" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024.jpg" alt="" class="wp-image-694602" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024.jpg 1022w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024-300x173.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024-768x444.jpg 768w" sizes="(max-width: 1022px) 100vw, 1022px" /></figure>
Finally, NEM stock appears to be sitting on a psychologically significant technical support line at $40 per share. While the security has been volatile since late October, the negative velocity has slowed in recent sessions. Therefore, intrepid investors may look to NEM as a bounce-back candidate.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">Fed Poised To Cut Interest Rates By 0.25% This Week: Here&#8217;s Why Your Focus Should Shift To Other Signals</a>
<h2 class="wp-block-heading">Laying the Framework of the Bull Call Spread</h2>
Of course, the easiest mechanism to speculate on Newmont stock is to buy the company's shares in the open market. However, this approach lacks leverage. Currently, the gold producer carries a market capitalization of nearly $46 billion. Simply put, there's likely not going to be much movement in its share price.
Subsequently, many retail traders turn to buying call options. According to data from the New York Stock Exchange, these market participants <a href="https://www.nyse.com/data-insights/trends-in-options-trading#:~:text=As%20Chart%201%20below%20shows,%2C%20reaching%2045%25%20in%20July.">tend to buy low-priced options</a>; that is, far out-the-money derivatives that have little chance of being net profitable.
A better approach may be to deploy the <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a>. Here, a trader buys a call for a particular options chain. However, the distinction between a straight call purchase and a bull call spread is that the trader simultaneously sells a call at a higher strike price (for the same expiration date).
To be fair, the structure of the trade caps the maximum reward (or payout) at the point represented by the higher short call strike. However, the benefit is twofold. First, the trader's net bullish position is discounted because the gross credit received from the short call helps partially offset the debit paid for the long call. Second, the threshold to profitability (i.e. the breakeven point) is effectively lowered by the aforementioned credit.
Therefore, the bull call spread allows traders to consider more probabilistically favorable transactions rather than taking longshot odds (such as "cheap" far OTM options).
<h2 class="wp-block-heading">Calculating an Ideal Spread for NEM Stock</h2>
With a popular security like Newmont stock, there are several bull call spreads to choose from. Ideally, though, the name of the game is to target spreads that are likely to be successful while also providing adequate payouts.
To better understand the market's anticipated move, traders can deploy a stochastic analysis to calculate the projected share price movement. This process involves multiplying the stock price with its option chain's implied volatility (IV) and time decay adjustment (or the square root of the calendar days to expiration divided by 365 days).
For example, the Dec. 27 options chain expires in 11 calendar days and features an <a href="https://optioncharts.io/options/NEM/volatility-skew?option_type=all&amp;expiration_dates=2024-12-27:w&amp;strike_range=all">average IV</a> of 28.75%. Assuming a share price of $40.05, the product of the three metrics comes out to just under $2. In other words, the market anticipates, at most, NEM stock to rise to $42.05 or, at worst, fall to $38.05 by Dec. 27.
A compelling idea within this options chain may be to consider the 39/41 bull call spread (buy the $39 call, sell the $41 call). At time of writing, the net debit paid comes out to $110 (which is also the most that can be lost in the trade). Should the trade be fully successful — which would involve NEM stock reaching $41 or higher — the reward would be $90 or a nearly 82% payout.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/12/42513807/trump-says-softbanks-100b-commitment-to-us-is-monumental-demonstration-of-confidence-in-americas-future">Trump Says SoftBank&#8217;s $100B Commitment To US Is &#8216;Monumental Demonstration Of Confidence In America&#8217;s Future&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Eurozone

Commodities

Options

Options Corner: German Crisis Opens Safe-Haven Play In Newmont Call Options

When Steve Menking first stepped onto Wall Street in his early 20s, he thought he had found his dream career. By 25, however, he realized the fast-paced life of an equities trader wasn't what he wanted.&nbsp;
"I watched colleagues my age – or younger – excelling in their careers," Menking recently told CNBC Make It. "But seeing people stay in the office until 1 a.m., I couldn't imagine that being my future. It just wasn't the lifestyle for me."
Don't Miss:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Menking, now 36, made a bold pivot that many dream of but few attempt: leaving finance to pursue his passion for teaching. He didn't want to start from scratch in the classroom, though. Instead, he turned to private tutoring.&nbsp;
What began as a career experiment in 2014 has grown into a thriving business, earning him over $500,000 annually – a figure he's on track to replicate in 2024. He works 20 to 25 hours a week from his Connecticut home, where he lives with his wife and three children.
"I realized teaching brought out a more patient, purpose-driven version of myself," Menking explained. His love for helping others learn stems from his time as a college teaching assistant and tutor, experiences that gave him a deep sense of meaning.
According to Grand View Research, the global private tutoring market is anticipated to reach 154.8 billion by 2030 and Menking's career is a prime example of why.&nbsp;
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
His journey began humbly: he submitted résumés to dozens of tutoring agencies in New York and created a profile on Wyzant, an online tutoring marketplace. Charging just under $100 an hour, he relied on his Wall Street expertise to carve a niche helping students with math, finance and accounting.
As word spread and referrals poured in, Menking gradually increased his rates. By 2017, he was earning $150 an hour. That same year, Thomas Howell, founder of Forum Education, reached out to him with a game-changing offer.&nbsp;
Forum's expansive network connected Menking with Ivy League students from schools like Princeton and Yale, catapulting his annual income from $95,000 to $200,000. "That's when my earning potential really took off," Menking recalled.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Today, Menking charges approximately $1,000 per hour. He works with undergraduates to simplify complex finance concepts, prepare for exams and nail internship interviews.&nbsp;
His clientele spans the nation and his schedule is as dynamic as the students he teaches. During summer, he might work eight to 10 hours a week, but that workload can climb to 40 hours in the lead-up to final exams.
Despite the occasional late-night email from a stressed student, Menking says tutoring offers an "extraordinary work-life balance." When he's not helping students crack tough problems, he's growing his business, Menking Tutoring LLC, which he launched in 2020. Beyond one-on-one sessions, the company offers online test prep and corporate training for budding investment banking analysts.
"There's no substitute for waking up every day knowing you're serving others in a way that aligns with your unique expertise," Menking said.&nbsp;
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

Wall Street Trader Turned Tutor Earns $500K A Year – 'There's No Substitute For Waking Up Knowing You're Serving Others'

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 6.37% on an annualized basis producing an average annual return of 17.68%. Currently, Chemed has a market capitalization of $8.09 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 10 years ago, it would be worth $507.92 today based on a price of $540.12 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734384608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Chemed 10 Years Ago Would Be Worth This Much Today